Im not sure RCE are being entirely upfront nor transparent. Have tried getting answers from James through email and phone calls. While R327 might be effective in UTI, the low plasma levels vs MID of eskape pathogens means challenges for 327 in sepsis indications. It was sepsis that was the original break through goal that the company was touting. Agree, silence on the H Pylori strategy is deafening.
Im not sure RCE are being entirely upfront nor transparent. Have...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.8¢ |
Change
0.003(0.65%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.0¢ | 38.0¢ | $4.167K | 10.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24610 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49817 | 1 |
View Market Depth
| Last trade - 15.44pm 31/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |